Paradigm engaged FB Rice in the development, registration and prosecution of our patents in order to secure a strong IP position. Paradigm has registered for the BME product Zilosul (tmr) and respiratory product Rhinosul (tmr) for Allergic Rhinitis.
Paradigm’s patent coverages includes
BME for treatment of bone marrow edema lesions with Pentosan Polysulphate covering Australia, USA, Japan, China, Taiwan, Singapore and other countries across the Asia Pacific
MPS patented for treatment with Pentosan Polysulphate covering the same regions
Alphavirus patented for treatment with Pentosan Polysulphate covering the same regions
Respiratory Disease for treatment with Pentosan Polysulphate covering the same regions
Trademarks - Paradigm has trademarked it's proprietary formulations for Pentosan Polysulphate Sodium for treatment of bone marrow edema - Zilosul and Rhinosul.
Any other concerns, they have pretty well stitched it up IMHO
Paradigm Ip Patents/ Trademarks
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.005(1.75%) |
Mkt cap ! $99.69M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $3.125K | 10.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16109 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 30000 | 1 |
View Market Depth
| Last trade - 10.32am 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
29.0¢ |
Change
0.005 ( 1.75 %) |
||||
| Open | High | Low | Volume | ||
| 29.0¢ | 29.0¢ | 29.0¢ | 700 | ||
| Last updated 10.18am 02/05/2024 ? | |||||
| PAR (ASX) Chart |